Furthermore, The EVOKE and EVOKE+ trials are pivotal phase 3 studies evaluating the potential of semaglutide, a GLP‐1 receptor agonist, as a disease‐modifying therapy for early‐stage symptomatic AD. This evidence concerns the gene GLP1R and Alzheimer disease.